JACOBS LEVY EQUITY MANAGEMENT, INC - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 84 filers reported holding CYTOMX THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$1,357,215
-51.3%
1,052,105
-35.1%
0.01%
-50.0%
Q2 2023$2,788,823
-2.4%
1,621,409
-14.3%
0.02%
-11.1%
Q1 2023$2,855,993
+169.7%
1,891,386
+185.8%
0.02%
+157.1%
Q4 2022$1,059,028
-33.3%
661,892
-39.5%
0.01%
-46.2%
Q3 2022$1,587,000
-3.3%
1,094,318
+22.1%
0.01%0.0%
Q2 2022$1,641,000
-42.8%
896,449
-16.6%
0.01%
-31.6%
Q1 2022$2,871,000
-46.5%
1,075,110
-13.2%
0.02%
-47.2%
Q4 2021$5,364,000
-24.4%
1,238,911
-11.1%
0.04%
-25.0%
Q3 2021$7,096,000
-20.7%
1,394,070
-1.4%
0.05%
-21.3%
Q2 2021$8,950,000
+93.8%
1,413,867
+136.7%
0.06%
+69.4%
Q1 2021$4,618,000
+16.7%
597,398
-1.1%
0.04%
+2.9%
Q4 2020$3,958,000
-3.2%
604,220
-1.7%
0.04%
-16.7%
Q3 2020$4,088,000
+15.9%
614,722
+45.1%
0.04%
+10.5%
Q2 2020$3,528,000
+89.3%
423,542
+74.3%
0.04%
+58.3%
Q1 2020$1,864,000
+1.5%
243,012
+9.9%
0.02%
+33.3%
Q4 2019$1,837,000
+197.7%
221,059
+164.3%
0.02%
+125.0%
Q3 2019$617,000
-24.8%
83,651
+14.4%
0.01%
-27.3%
Q2 2019$821,000
+7.9%
73,151
+3.3%
0.01%0.0%
Q1 2019$761,000
+60.9%
70,801
+126.2%
0.01%
+37.5%
Q4 2018$473,000
-18.3%
31,3010.0%0.01%0.0%
Q3 2018$579,000
-26.3%
31,301
-9.0%
0.01%
-33.3%
Q2 2018$786,000
+17.1%
34,381
+45.7%
0.01%
+9.1%
Q1 2018$671,000
+0.3%
23,601
-25.6%
0.01%
-8.3%
Q4 2017$669,000
+200.0%
31,701
+158.8%
0.01%
+200.0%
Q3 2017$223,00012,2500.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 1,500,000$7,635,0001.78%
Altium Capital Management LP 1,233,642$6,279,0001.65%
RA Capital Management 3,500,000$17,815,0000.25%
Soleus Capital Management, L.P. 261,050$1,329,0000.21%
Affinity Asset Advisors, LLC 125,000$636,0000.16%
PLATINUM INVESTMENT MANAGEMENT LTD 1,078,103$5,488,0000.16%
Point72 Asset Management, L.P. 6,303,025$32,082,0000.14%
GSA CAPITAL PARTNERS LLP 249,146$1,268,0000.13%
Candriam S.C.A. 3,305,940$16,826,0000.11%
RTW INVESTMENTS, LP 1,400,939$7,131,0000.11%
View complete list of CYTOMX THERAPEUTICS INC shareholders